The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

OTOR  -  otoraplin

Homo sapiens

Synonyms: FDP, Fibrocyte-derived protein, MIAL, MIAL1, Melanoma inhibitory activity-like protein, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of OTOR

  • Three patients had evidence of venous thrombosis and in 2 additional patients a low fibrinogen level together with increased amounts of FDP/fdp and a positive ethanol test indicated disseminated intravascular coagulation (DIC) [1].
  • Of 15 patients with suspected intravascular coagulation but normal FDP, protein C was decreased in 5 individuals; 3 of these 5 patients had liver disease [2].
  • Blood tests for fibrinogen/fibrin degradation products (FDP/fdp) and soluble fibrin complexes (SFC) were performed in 100 patients at high risk for thromboembolism in order to assess the diagnostic value of these determinations in patients suspected to have pulmonary embolism [3].
  • Measurement of FDP/fdp and SFC can help identify patients at risk of recurrent thromboembolism if performed serially during treatment [4].
  • RESULTS--The increment of serum FDP level after venous occlusion was significantly less in patients with NIDDM (60.6 +/- 33.5 to 81.5 +/- 49.6 ng/ml) and in those with cerebrovascular accident (101.4 +/- 51.5 to 116.2 +/- 47.2 ng/ml) than in control subjects (79.9 +/- 41.0 to 148.8 +/- 65.4 ng/ml) [5].

Psychiatry related information on OTOR

  • The purpose of this study was to determine the levels of awareness of FDP among mental health practitioners and their sources of information [6].
  • Overall, 102 of the 123 subjects (83%) had stopped smoking by the end of the FDP, and self-declared smoking cessation rate was 25% after one year [7].
  • 3) The FDP value showed changes by load which was so light that it did not induce functional deterioration detectable by the response time or the flicker value which was considered to be one of effective physiological indices [8].
  • Through above examinations, FDP values of serum and urine seem to be useful as an index of transient fatigue; especially they can well reflect mental fatigue which cannot be indicated well by other biochemical indices [8].

High impact information on OTOR

  • FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line [9].
  • Glycolate kinase activity was detected in the presence of FDP or glucose-1,6-P2 [10].
  • The pH optimum of the reaction was over 10.5 With 10 mumol/L FDP, 500 mumol/L glucose-1,6-P2, 2 mmol/L ATP, 5 mmol/L MgCl2, and 50 mmol/L glycolate at pH 7.5, glycolate kinase activity was calculated to be approximately 0.0013 U/mL RBC [10].
  • Protein C antigen concentration was determined in plasmas from normals (n = 40) and from 38 patients with intravascular coagulation as evidenced by positive FDP (greater than micrograms/ml) [2].
  • During the course of a study aimed at isolating transcripts specifically or preferentially expressed in the inner ear, we identified a novel gene, encoding a fibrocyte-derived protein, that we named Fdp [11].

Chemical compound and disease context of OTOR

  • The direct latex-agglutination kit for FDP/fdp appears to have appropriate sensitivity to serve as a screening test for acute pulmonary embolism in patients not receiving heparin therapy [12].
  • In seven out of seven patients suffering from oral submucous fibrosis (OSMF), we detected circulating molecules that are immunologically similar to fibrinogen (MISFI), as suggested by the hemagglutination inhibition studies using the FDP Kit (Wellcome) and by paracoagulation tests such as serial dilution protamine tests [13].
  • In this group we observed a prompt and persistent increase of G6P, F6P and FDP levels over the three hours hyperglycemia phase which has been induced by glucose load [14].
  • The authors report the results obtained investigating PT - PTT - Fbg - Alcohol test - FDP - AT III in the serum and FDP in the ascitic fluid of 18 patients with ovarian cancer, 2 patients with pelvic relapse of cervical cancer and 10 patients with cirrhosis of the liver [15].

Biological context of OTOR

  • Sequence homology confirms the highly conserved SH3 structure present also in MIA, OTOR and MIA2 [16].
  • We examined hemostatic indicators in relation to DIC score: prothrombin time (PT) ratio, FDP, platelet count, and fibrinogen levels were found to be important indicators for the diagnosis of DIC, but not for Pre-DIC [17].
  • Compared to patients with normal fibrinogen (n = 360) patients with HF had significantly elevated markers of activation of coagulation (TAT, F1.2, FPA) and fibrinolysis (D-dimer, FDP) indicating that disseminated intravascular coagulation/hyperfibrinolysis was the cause of hypofibrinogenemia [18].
  • After the run, in all 3 years, APTT showed shortening (p < 0.001); prothrombin time and plasma fibrinogen were not significantly altered; euglobulin lysis time was shorter (p < 0.001) and FDP increased (p < 0.001); PSPT became positive in all subjects, whereas the ehtanol gelation test remained negative; no cryofibrinogen was detected [19].
  • A sequential study of kaolin cephalin clotting time (KCCT), prothrombin time (PT), thrombin time (TT), plasma fibrinogen and serum FDP was conducted during the first four weeks of life on term and preterm babies [20].

Anatomical context of OTOR


Associations of OTOR with chemical compounds

  • The addition of pyruvate significantly reduced the fructose 1,6-bisphosphate (FDP) content and free cytoplasmic NADH/NAD ratio, estimated by increased pyruvate/lactate ratio in NG and HG cells exposed to H2O2 [24].
  • FDP/fdp values were elevated by the latex-agglutination kit when normal by the TRCHII for 79 (13%) samples, and the reverse was true for 20 (3%) samples [12].
  • In all subjects studied, 0.5 mM FDP activated and 2 mM L-alanine inhibited the enzyme [23].
  • BACKGROUND AND METHODS: We demonstrated earlier in our laboratories that fructose-1,6-bisphosphate (FDP) would improve the outcome of hypoxic ischemic injury to the brain in the adult rabbit [25].
  • Low molecular weight, dialysable peptides (FDP) showed the highest dose dependent, histamine releasing activity [26].

Other interactions of OTOR

  • The results of this study suggest that the MIA protein and the recently identified highly homologous fibrocyte-derived protein (FDP)/MIA-like (MIAL) constitute a new family of secreted proteins that adopt an SH3 domain-like fold in solution with expanded ligand interactions [27].

Analytical, diagnostic and therapeutic context of OTOR

  • No other human tissue, except fetal brain, showed expression of MIAL when analyzed by in situ hybridization or reverse transcription-polymerase chain reaction [21].
  • In the FUT group, serum concentrations of beta-thromboglobulin (307 +/- 102 versus 537 +/- 391 ng/mL, P < .05), PIC (3.6 +/- 1.7 versus 5.8 +/- 3.8 micrograms/mL, P < .05) and FDP (20.2 +/- 7.0 versus 41.4 +/- 11.9 ng/mL, P < .01) were significantly lower than those in the control group at the end of CPB [28].
  • Moreover, it was possible to isolate SFC from FDP using gel filtration after treatment with thrombin and t-AMCHA [29].
  • The cleavage of fibrinogen and fibrin by PMN elastase, independent of plasmin, was indicated by the presence of the fragments in immunoprecipitated plasma from the patient corresponding to elastase-induced FDP D and DD fragments and the absence of fragments corresponding to plasmin-induced FDP D and DD fragments on SDS-PAGE [30].
  • The objective of this study was to evaluate the AuraTek FDP rapid immunoassay device for the detection of urinary fibrin/ fibrinogen degradation products associated with bladder cancer [31].


  1. Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Mombelli, G., Roux, A., Haeberli, A., Straub, P.W. Blood (1982) [Pubmed]
  2. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Griffin, J.H., Mosher, D.F., Zimmerman, T.S., Kleiss, A.J. Blood (1982) [Pubmed]
  3. Diagnostic value of tests of fibrin metabolism in patients predisposed to pulmonary embolism. Bynum, L.J., Crotty, C.M., Wilson, J.E. Arch. Intern. Med. (1979) [Pubmed]
  4. Tests of fibrin metabolism in recurrent venous thromboembolism. Bynum, L.J., Parkey, R.W., Wilson, J.E. Arch. Intern. Med. (1977) [Pubmed]
  5. Vascular dysfunction detected by a simplified venous occlusion test in NIDDM patients. Mizuno, A., Isobe, J., Shima, K. Diabetes Care (1993) [Pubmed]
  6. Factitious disorder by proxy: awareness among mental health practitioners. Ostfeld, B.M., Feldman, M.D. General hospital psychiatry. (1996) [Pubmed]
  7. Five-day plan for smoking cessation using group behaviour therapy. Frikart, M., Etienne, S., Cornuz, J., Zellweger, J.P. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology. (2003) [Pubmed]
  8. Changes in the FDP (fibrin and fibrinogen degradation products) value under mental and physical stress. II. Simultaneous observations of FDP and other indices of fatigue in persons under experimentally loaded stress. Omoto, M., Furuichi, S., Imai, T., Nomura, R., Hokama, Y., Igarashi, M. Sangyō igaku. Japanese journal of industrial health. (1982) [Pubmed]
  9. FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Hamaguchi, M., Morishita, Y., Takahashi, I., Ogura, M., Takamatsu, J., Saito, H. Blood (1991) [Pubmed]
  10. Glycolate kinase activity in human red cells. Fujii, S., Beutler, E. Blood (1985) [Pubmed]
  11. Fdp, a new fibrocyte-derived protein related to MIA/CD-RAP, has an in vitro effect on the early differentiation of the inner ear mesenchyme. Cohen-Salmon, M., Frenz, D., Liu, W., Verpy, E., Voegeling, S., Petit, C. J. Biol. Chem. (2000) [Pubmed]
  12. Comparison of a direct latex-agglutination technic with the tanned red cell hemagglutination inhibition immunoassay (TRCHII) for semiquantitation of fibrinogen/fibrin degradation products. Wilson, J.E., Thornton, R.D. Am. J. Clin. Pathol. (1976) [Pubmed]
  13. Hypercoagulation and fibrinolysis in oral sub-mucous fibrosis. Phatak, A.G. Am. J. Clin. Pathol. (1984) [Pubmed]
  14. Erythrocyte concentration of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. Scionti, L., Puxeddu, A., Calabrese, G., Gatteschi, C., De Angelis, M., Bolli, G., Compagnucci, P., Calafiore, R., Brunetti, P. Horm. Metab. Res. (1982) [Pubmed]
  15. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies. Varcaccio-Garofalo, G., Selvaggi, L., Capozza, G., Orlando, E., Ferreri, R., Restaino, A. Eur. J. Gynaecol. Oncol. (1982) [Pubmed]
  16. Characterization and expression pattern of the novel MIA homolog TANGO. Bosserhoff, A.K., Moser, M., Buettner, R. Gene Expr. Patterns (2004) [Pubmed]
  17. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Wada, H., Wakita, Y., Nakase, T., Shimura, M., Hiyoyama, K., Nagaya, S., Mori, Y., Shiku, H. Thromb. Haemost. (1995) [Pubmed]
  18. Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis. Weltermann, A., Pabinger, I., Geissler, K., Jäger, U., Gisslinger, H., Knöbl, P., Eichinger, S., Kyrle, P.A., Valent, P., Speiser, W., Schwarzinger, I., Mannhalter, C., Lechner, K. Leukemia (1998) [Pubmed]
  19. Marathon Run III: effects on coagulation, fibrinolysis, platelet aggregation and serum cortisol levels. A 3-year study. Mandalaki, T., Dessypris, A., Louizou, C., Panayotopoulou, C., Dimitriadou, C. Thromb. Haemost. (1980) [Pubmed]
  20. Hemostatic parameters in newborn--II. Sequential study during the first four weeks of life. Kolindewala, J.K., Dube, B., Bhargava, V., Dube, R.K., Kota, V.L., Das, B.K. Thromb. Haemost. (1986) [Pubmed]
  21. Identification and characterization of an inner ear-expressed human melanoma inhibitory activity (MIA)-like gene (MIAL) with a frequent polymorphism that abolishes translation. Rendtorff, N.D., Frödin, M., Attié-Bitach, T., Vekemans, M., Tommerup, N. Genomics (2001) [Pubmed]
  22. Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in vitro. Van Leer, C., Stutz, M., Haeberli, A., Geiser, T. Thromb. Haemost. (2005) [Pubmed]
  23. Kinetic properties of pyruvate kinase in human maternal leukocytes in fetal malnutrition. Mameesh, M.S., Metcoff, J., Costiloe, P., Crosby, W. Pediatr. Res. (1976) [Pubmed]
  24. Pyruvate improves deleterious effects of high glucose on activation of pentose phosphate pathway and glutathione redox cycle in endothelial cells. Kashiwagi, A., Nishio, Y., Asahina, T., Ikebuchi, M., Harada, N., Tanaka, Y., Takahara, N., Taki, H., Obata, T., Hidaka, H., Saeki, Y., Kikkawa, R. Diabetes (1997) [Pubmed]
  25. Fructose-1,6-bisphosphate, when given immediately before reoxygenation, or before injury, does not ameliorate hypoxic ischemic injury to the central nervous system in the newborn pig. LeBlanc, M.H., Farias, L.A., Evans, O.B., Vig, V., Smith, E.E., Markov, A.K. Crit. Care Med. (1991) [Pubmed]
  26. Anti-inflammatory drugs modulate histamine release from mast cells induced by fibrinogen degradation products. Wojtecka-Lukasik, E., Stachurska, J., Kopeć, M., Maśliński, S. Ann. Rheum. Dis. (1988) [Pubmed]
  27. Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains. Stoll, R., Renner, C., Buettner, R., Voelter, W., Bosserhoff, A.K., Holak, T.A. Protein Sci. (2003) [Pubmed]
  28. Nafamostat mesilate reduces blood loss during open heart surgery. Murase, M., Usui, A., Tomita, Y., Maeda, M., Koyama, T., Abe, T. Circulation (1993) [Pubmed]
  29. A simple rapid method for isolating soluble fibrin complexes from fibrinogen by treatment with thrombin and t-AMCHA. Hayashi, S., Yamada, K. Thromb. Haemost. (1980) [Pubmed]
  30. An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia. Iijima, K., Murakami, F., Horie, Y., Nakamura, K., Ikawa, S., Soe, G., Kohno, I., Nakayasu, H., Shimomura, T., Takahashi, K. Thromb. Haemost. (1996) [Pubmed]
  31. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. Schmetter, B.S., Habicht, K.K., Lamm, D.L., Morales, A., Bander, N.H., Grossman, H.B., Hanna, M.G., Silberman, S.R., Butman, B.T. J. Urol. (1997) [Pubmed]
WikiGenes - Universities